Pertussis vaccines: acellular versus whole-cell.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 8649299.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Acellular pertussis vaccines containing purified Bordetella pertussis antigens have now been extensively field tested. They produce a significantly lower rate of reactions than whole-cell vaccines and their efficacy is either comparable or superior. At least three antigens appear necessary for good protection: pertussis toxoid, filamentous haemagglutinin and pertactin (an outer-membrane protein); fimbrial agglutinogens are probably not needed. It is hoped that a cellular pertussis vaccine will soon be licensed in Australia for both primary and booster vaccination.